Archive for the ‘Therapeutic Classification’ Category

Luliconazole a Gold Standard Treatment for Fungal Infections

Friday, May 22nd, 2015

Luliconazole CAS 187164-19-8Known as the brand name azole antifungal cream Luzu, which is marketed by Valeant Pharmaceuticals, Luliconazole 1% cream remains a gold standard treatment for a variety of fungal infections. Luliconazole is approved by the FDA to treat the following:

  • interdigital tinea pedis, or athlete’s foot
  • tinea corporis, also known as ringworm
  • tinea cruris, coined jock itch

As the first topical antifungal agent approved to treat tinea corporis and tinea cruris with a once daily treatment regimen lasting only a week, Luliconazole works quickly and effectively. Luliconazole is equally as effectual for treating interdigital tinea pedis, however the recommended dosage is one application daily for two weeks’ time. The original FDA approval in early 2013 was based on three successful trials which involved 679 adults suffering from tinea pedis and or tinea cruris. The first two trials focused on patients with tinea pedis, with the study goal being a complete clearance of the fungal infection at the four week mark. Trial group #1 demonstrated that 26 percent of patients treated with Luliconazole, once a day for two weeks, had a complete recovery and showed no signs of fungal infection. Only 2 percent of the placebo group in trial group #1 recovered. Trial group #2, which also focused on patients with tinea pedis, showed that 14 percent of patients experienced total healing after two weeks therapy versus 3 percent of the placebo group. The third group of patients with tinea cruris were assessed three weeks post-treatment for complete clearance of their fungal infection. A healthy 21 percent of participants experienced a total recovery with no signs of the fungal infection after just one week. Only 4 percent of the placebo group, however, showed complete clearance at the three week mark. Adverse effects were nonexistent, with a slight number of patients complaining about mild application site irritation.

As a safe and efficacious topical treatment for fungal infections Luliconazole continues to succeed in post marketing studies. Luliconazole works by blocking fungal ergosterol biosynthesis through the inhibition of the lanosterol demethylase enzyme. While this therapy is administered topically some systemic absorption has been documented, with plasma levels ranging from approximately 1 to 7 ng/mL.

LGM Pharma can assist clients as a supplier/distributor of the API Luliconazole CAS# 187164-19-8 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Sofosbuvir and Ledipasvir Offers 6 Week Hepatitis C Cure

Wednesday, May 20th, 2015

Sofosbuvir and Ledipasvir Hep CSofosbuvir is popular in the pharmaceutical headlines as of late, with more positive news for the patient population with Hepatitis C. An NIH (National Institute of Allergy and Infectious Diseases) study released exciting data which showed the use of Sofosbuvir and Ledipasvir elicited a cure rate in only six weeks’ time for patients with the Hepatitis C virus. This phenomenal time frame was unexpected by study investigators, but certainly welcomed by patients and practitioners. The study involved adult patients with Hepatitis C infections. Taking place at the National Institutes of Health, the aforementioned patients received a combination of three direct-acting drug therapies. This oral course of treatment was offered for approximately six and twelve weeks and the results were presented in the latest issue of The Lancet. The first trial saw 20 trial participants who received Sofosbuvir alongside both Ledipasvir and an experimental drug coined GS-9669. None of the clinical trial patients had previously undergone treatment of any kind for the Hepatitis C virus. Remarkably 19 of these patients who received these three therapies had a complete recovery at the 12 week mark. A second group of 20 patients were given a combination treatment of Sofosbuvir, Ledipasvir and a different experimental drug, coined GS-9451 for 6 weeks’ time. Again, this patient group had not been previously treated for the Hepatitis C virus. At the conclusion of the six week therapy a startling 19 of these patients exhibited zero signs of the Hepatitis C virus. Finally, a third group of 20 patients were administered Sofosbuvir and Ledipasvir only. This group also showed an astounding cure rate, with all 20 participants demonstrating no signs of the disease at the 12 week mark. The six week trial group’s success proved that a shorter time period for treatment was as efficacious in this instance as compared to a 12 week course of treatment.

HepCIn addition to patient cure rates being incredibly good, there were no reports of patients experiencing adverse effects from any of these Hepatitis C drug therapy combinations. The advent of these novel therapies, to be dispensed in shorter periods of time makes treatment for this virulent disease easier and efficacious for a wide swath of patients. The need for immediate treatment is urgent for patients suffering from the Hepatitis C virus, as roughly 85 percent of untreated or improperly treated cases end up leading to chronic Hepatitis C. The development of this chronic and long-term liver infection is devastating for patients.

LGM Pharma can assist clients as a supplier/distributor of the APIs Ledipasvir, CAS # 1256388-51-8 and Sofosbuvir, CAS # 1190307-88-0 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Brimonidine Effectual for Soaring Rates of Glaucoma

Thursday, May 14th, 2015

BrimonidineBy 2020 Glaucoma is predicted to affect over 80 million people worldwide as one of the leading causes of vision loss in adults. Approximately 10 percent of the patients diagnosed with Glaucoma will become bilaterally blind from this disease. Treatment to effectively and safely lower intraocular pressure is a must, with a growing rate of patients needing tolerable therapy expected in the next half decade. Brimonidine has, and continues to be an efficacious treatment for lowering intraocular pressure (IOP) in patients by delaying the progressive degeneration of retinal ganglion cells, which leads to elevated IOP. Known as the brand name eye drop Alphagan, which is marketed by Allergan, Brimonidine is now offered in a generic formula from Falcon Pharmaceuticals. As a selective α2-adrenergic receptor agonist, Brimonidine has also proven in a plethora of studies to have protective effects on oxidative stress and glutamate neurotoxicity in the eye. The typical dosage of Brimonidine is one drop in each affected eye, three times a day. This dosing regimen also aids in decreasing fluid production in the eye by increasing draining effectively.

People with Glaucoma in 2010

Brimonidine is available as a 0.15% Ophthalmic Solution and can be used alongside the majority of other prescribed eye drops, as long as dosages are spaced at least five minutes apart. Adverse effects from Brimonidine Tartrate are rare, and mild side effects commonly reported include nasal dryness and slight taste perversion. A unique and easy to use Drop-tainer dispenser, marketed by Alcon is available for dosing Brimonidine, in sizes of 5mL, 10mL and 15mL.

LGM Pharma can assist clients as a supplier/distributor of the API’s Brimonidine CAS# 59803-98-4 and Brimonidine Tartrate CAS# 79570-19-7 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Bimatoprost Lower Intraocular Pressure and Increases Eyelash Growth

Monday, May 11th, 2015

Bimatoprost Lower Intraocular Pressure and Increases Eyelash Growth

Bimatoprost opthamolic solution has been known for being effectual at lowering intraocular pressure in adult patients. A new benefit of Bimatoprost has stolen the pharmaceutical headlines, however, with the advent of Latisse, for treating hypotrichosis of the eyelashes. Touted by long time movie star and model Brooke Shields, Latisse is recommended for people who wish to increase their growth, length, darkness and thickness of their eyelashes. This 0.03% solution of Allergan’s Bimatoprost has proven in a plethora of studies to be effective and safe for patients who use this therapy for hypotrichosis of the eyelashes, as well as elevated intraocular pressure.

Patients who are utilizing Bimatoprost for increased eyelash growth utilize this therapy by applying one full sterile applicator of this solution to the skin of their upper eyelid, specifically at the base of the eyelashes. As a viable prostaglandin analog Latisse (Bimatoprost 0.03% opthamolic solution) has not caused serious adverse side effects. A minority of patients have complained of a darkened brown area of their iris developing, particularly for people who have hazel eyes. The upside of this product is the ability for patients to access it via medical spas and coordinate their treatments alongside other beauty regimens, such as Botox. Success is an understatement when referring to Bimatoprost as an eyelash enhancer product. Last year 74 million dollars of Latisse was sold, and figures are expected to double in 2015. Net sales overall are projected by pharmaceutical analysts to ultimately exceed 500 million dollars annually if patients end up being able to access this treatment without a prescription.

Bimatoprost is also known as the brand name eye drop Lumigan, which is also marketed by Allergan for decreasing intraocular eye pressure in patients at risk of getting glaucoma. LGM Pharma can assist clients as a supplier/distributor of the API Bimatoprost, CAS #155206-00-1 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Almotriptan Patent to Expire in May 2015

Tuesday, May 5th, 2015

almotriptanKnown as the brand name migraine treatment Axert, marketed by Ortho-McNeil Pharmaceuticals, Almotriptan’s patent protection expires in May 2015. This is exciting news for research and development teams who are currently seeking to provide migraine sufferers with additional therapies. Almotriptan, or Axert, is currently FDA approved to treat migraine with or without aura in adults and adolescents ages 12 to 17. Clinical trials and post marketing reports have shown encouraging results from patients of all ages, with few adverse effects noted. Common side effects reported include slight nausea, dry mouth and a tired feeling.

The publication Headache: The Journal of Head and Face Pain revealed overwhelming support for the use of various triptans for migraine patients if current therapies were inadequate. Clinical data from a swath of patients that previously found Sumatriptan (Imitrex) to be ineffective were instead administered Almotriptan at the onset of their next migraine. A sizable 47 percent of these patients who received Almotriptan experienced total pain relief two hours post dosage. Researchers have come to understand that not all migraine patients are the same, and not all triptans are equal either. As an efficacious serotonin (5HT) inhibitor triptan, Almotriptan has become a viable option for patients who find a lack of efficacy or devastating side effects occur from other triptan therapies.

According to the Migraine Research Foundation one in four U.S. households has a person who suffers from migraines. Roughly 18 percent of women and 6 percent of men are afflicted with migraine headaches as well. Additionally, migraine headaches rank in the top 20 of the most disabling medical illnesses worldwide. Continued R&D is needed to combat the great need for innovative therapies to treat this growing patient population. LGM Pharma can assist clients as a supplier/distributor of the API Almotriptan, CAS # 154323-57-6, for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.